Aberrant phosphotyrosine-based signaling is a hallmark of cancer, and gliomas are no exception; tyrosine kinase membrane receptors like EGFR, ERBB2, PDGFRA, MET and VEGFR2 have been implicated in glioma growth, angiogenesis and cell motility [7]. Here, ERBB2 is linked to central nervous system cancer.